Otsuka Pharmaceutical Co., Ltd was 4D Molecular Therapeutics’s largest revenue line in fiscal 2025, bringing in $85.00M of $85.21M (100%).
| Counterparty Name | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Otsuka Pharmaceutical Co., Ltd | — | — | — | $85.00M | |||
| Astellas | — | $20.01M | — | — | |||
| Roche | — | — | — | — | |||
| Uniqure | $3.09M | $567.00K | — | — | |||
| Astrazeneca | — | — | — | — | |||
| Cff | $35.00K | $148.00K | $37.00K | $209.00K | |||
| Benitec | — | — | — | — | |||
| Total | $3.13M | $20.72M | $37.00K | $85.21M |
4D Molecular Therapeutics brought in $85.21M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. 4D Molecular Therapeutics regrouped these revenue lines after fiscal 2024, so the total does not compare directly with that year's $37.00K. Otsuka Pharmaceutical Co., Ltd was the largest at $85.00M (99.8%), ahead of Cff at $209.00K (0.2%).
4D Molecular Therapeutics began breaking out Otsuka Pharmaceutical Co., Ltd in fiscal 2025, when it brought in $85.00M. 4D Molecular Therapeutics stopped reporting Astellas ($20.01M in fiscal 2023) and Uniqure ($567.00K in fiscal 2023) as separate revenue lines.
Japan was 4D Molecular Therapeutics’s largest region in fiscal 2025, bringing in $85.00M of $85.21M (100%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Japan | — | — | — | $85.00M | |||
| Switzerland | — | — | — | — | |||
| United States | $35.00K | $20.16M | $37.00K | $209.00K | |||
| Netherlands | $3.09M | $567.00K | — | — | |||
| Australia | — | — | — | — | |||
| Total | $3.13M | $20.72M | $37.00K | $85.21M |
4D Molecular Therapeutics brought in $85.21M from its two regions in fiscal 2025, the year ended December 31, 2025. 4D Molecular Therapeutics regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $37.00K. Japan was the largest at $85.00M (99.8%), ahead of United States at $209.00K (0.2%).
4D Molecular Therapeutics began breaking out Japan in fiscal 2025, when it brought in $85.00M. 4D Molecular Therapeutics stopped reporting Netherlands as a separate region after fiscal 2023, when it brought in $567.00K.
4D Molecular Therapeutics (FDMT) reports its revenue by counterparty name and by geography. In fiscal 2025, Otsuka Pharmaceutical Co., Ltd was its largest revenue line, bringing in $85.00M (99.8% of the total), followed by Cff at $209.00K (0.2%).
Otsuka Pharmaceutical Co., Ltd was 4D Molecular Therapeutics' largest revenue line in fiscal 2025, bringing in $85.00M, or 99.8% of the $85.21M total across its two revenue lines.
Japan was 4D Molecular Therapeutics' largest region in fiscal 2025, bringing in $85.00M, or 99.8% of the $85.21M total across its two regions.
Every figure comes from 4D Molecular Therapeutics' annual financial filings, as reported. Each line keeps the name 4D Molecular Therapeutics gives it, and years follow its fiscal calendar.
4D Molecular Therapeutics' revenue by counterparty name goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.